Brands often focus on market share against direct competitors. However, the real competition can be invisible factors like a patient's belief system, inertia, or logistical hurdles in the healthcare system that cause them to delay or abandon treatment altogether.

The overactive bladder market is chronically underserved not due to a lack of options, but because existing treatments (drugs linked to dementia, expensive implants) are so flawed that 78% of patients refuse them. This massive patient drop-off signals a prime opportunity for safer, more accessible alternatives.

In a crowded market like atopic dermatitis, a safe oral drug can carve out a significant niche. Corvus's soquolitinib is positioned to compete against the injectable standard of care (Dupixent) and existing oral JAK inhibitors, which carry black box warnings. This 'safe oral' profile meets a major unmet need for both doctors and patients.

The market soured on Nektar's alopecia data because of low overall response rates. This misses that the drug is slow-acting and nearly half the patients dropped out before it could take effect. The real efficacy is likely much higher among patients who complete the full treatment course.

Unlike conditions with transient flare-ups, missing a few doses of a fast-acting alopecia drug can cause catastrophic hair loss, erasing years of progress. A long-acting injectable provides a crucial buffer against real-world issues like insurance delays, making it a uniquely superior option for patients despite the injection route.

Protagonist believes its oral IL-23 blocker will not just compete with existing injectables but will capture a new market. They target the over 50% of eligible patients who currently take no therapy due to a dislike of injections or the safety profiles of other oral options, thereby expanding the total addressable market.

Upcoming oral psoriasis drugs from J&J, Alumis, and Takeda offer efficacy close to injectables but with greater convenience. This strategy is not about stealing market share but about massive market expansion, targeting millions of patients using only topicals and potentially growing the market to over $40 billion.

Viridermix's strategy for its oral hair loss drug isn't just about convenience. The company re-engineered immediate-release minoxidil to provide consistent exposure to hair follicles, aiming to maximize growth while blunting the plasma spikes responsible for the original blood pressure drug's cardiac side effects.

The boom in 'baldness stocks' reveals a pattern for investors and entrepreneurs: target large, stagnant industries that have seen no significant innovation in decades. Just as Ozempic revitalized the weight-loss market, new treatments for hair loss are creating massive value in a field previously dominated by a single legacy product (Rogaine).